Structure Enterprise Value Multiple from 2010 to 2024
| GPCR Stock | 52.00 1.96 3.92% |
Enterprise Value Multiple | First Reported 2010-12-31 | Previous Quarter (13.49) | Current Value (14.17) | Quarterly Volatility 25.2 K |
Check Structure Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Structure Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 247.8 K, Net Interest Income of 14.1 M or Depreciation And Amortization of 996.6 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 3.47. Structure financial statements analysis is a perfect complement when working with Structure Therapeutics Valuation or Volatility modules.
Structure | Enterprise Value Multiple |
Latest Structure Therapeutics' Enterprise Value Multiple Growth Pattern
Below is the plot of the Enterprise Value Multiple of Structure Therapeutics American over the last few years. It is Structure Therapeutics' Enterprise Value Multiple historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Structure Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Enterprise Value Multiple | 10 Years Trend |
|
Enterprise Value Multiple |
| Timeline |
Structure Enterprise Value Multiple Regression Statistics
| Arithmetic Mean | (45,546) | |
| Coefficient Of Variation | (55.25) | |
| Mean Deviation | 20,915 | |
| Median | (59,806) | |
| Standard Deviation | 25,166 | |
| Sample Variance | 633.3M | |
| Range | 59.8K | |
| R-Value | 0.77 | |
| Mean Square Error | 276.9M | |
| R-Squared | 0.59 | |
| Significance | 0.0008 | |
| Slope | 4,337 | |
| Total Sum of Squares | 8.9B |
Structure Enterprise Value Multiple History
About Structure Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Structure Therapeutics income statement, its balance sheet, and the statement of cash flows. Structure Therapeutics investors use historical funamental indicators, such as Structure Therapeutics's Enterprise Value Multiple, to determine how well the company is positioned to perform in the future. Although Structure Therapeutics investors may use each financial statement separately, they are all related. The changes in Structure Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Structure Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Structure Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Structure Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Enterprise Value Multiple | (13.49) | (14.17) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Tools for Structure Stock Analysis
When running Structure Therapeutics' price analysis, check to measure Structure Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Structure Therapeutics is operating at the current time. Most of Structure Therapeutics' value examination focuses on studying past and present price action to predict the probability of Structure Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Structure Therapeutics' price. Additionally, you may evaluate how the addition of Structure Therapeutics to your portfolios can decrease your overall portfolio volatility.